The new guidelines, published in the Journal of the American Academy of Dermatology (JAAD), will guide dermatologists in deciding the best possible prevention and treatment options for pediatric ...

HealthDay News — Treatment with upadacitinib is safe and effective for adults and adolescents with nonsegmental vitiligo (NSV), according to a study presented at the annual meeting of the American ...

Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits for outcomes in psoriatic arthritis (PsA) versus IXE alone ...

At the American Academy of Dermatology (AAD) 2026 Annual Meeting, experts emphasized the value of in-person networking, ...

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...

Presentations at the 2026 meeting of the American Academy of Dermatology not only demonstrate the therapeutic potential of ...

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research sessionAcross the COAST 1, ...

For adults with dermatomyositis, brepocitinib, an oral tyrosine kinase 2/Janus kinase 1 inhibitor, demonstrates significant ...

Galderma (SIX: GALD), the pure-play dermatology category leader, will present the latest updates on its innovations across its broad portfolio at the 2026 American Academy of Dermatology (AAD) Annual ...

Soligenix (NASDAQ: SNGX) announced that new supportive trial data for HyBryte(TM) in the treatment of cutaneous T-cell ...

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.